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Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the COVID-19 pandemic. Since its
first report in December 2019, despite great efforts made in almost every country worldwide, this disease continues to
spread globally, especially in most parts of Europe, Iran, and the United States. Here, we update the recent
understanding in clinical characteristics, diagnosis strategies, as well as clinical management of COVID-19 in China as
compared to Italy, with the purpose to integrate the China experience with the global efforts to outline references for
prevention, basic research, treatment as well as final control of the disease. Being the first two countries we feel
appropriate to evaluate the evolution of the disease as well as the early result of the treatment, in order to offer a
different baseline to other countries. It is also interesting to compare two countries, with a very significant difference in
population, where the morbidity and mortality has been so different, and unrelated to the size of the country.
Facts
● The Covid-19 pandemic exploded first in China and
subsequently in Italy. We therefore compared these
two countries with the earliest and strongest impact
on the population.
● With over 5,525,245 cases, including 2,315,909
recovered and 347,108 deaths worldwide as of 25
May 2020, the spread of infection still seems difficult
to contain.
● Both the availability of intensive care and the local
medical heath system on the territory may be
responsible for the vast heterogeneity in infection
containment and mortality.
Open questions
● The therapy, especially in the advanced stages, seems
complicated, and we are waiting the outcome of
several hundreds of clinical trials, often duplicated
and non-coordinated. Major drugs are mostly non-
viral-specific: hydroxychloroquine, lopinavir/
ritonavir, remdesivir, convalescent plasma/
monoclonal antibody, camostat, and ivermectin.
New drug development is clearly the first priority.
● The role of immunity is crucial both to overcame the
acute phase and for establishing the vaccine.
● Exit from the acute phase and establishing the new
protocol for the post-acute phase is of utter priority.
The severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) is responsible for the COVID-19 disease as
originally shown in Wuhan, China, as early as docu-
mented from 1 December 2019 (ref. 1). On 11 March
2020, the WHO announced COVID-19 as a worldwide
pandemic, 2 months after the official disclosure from the
Chinese government of the actual cluster epidemics in
Whuan2.
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As of 25 May 2020, there were over 5,525,245 confirmed
COVID-19 cases worldwide, of which more than 30%
cases in the EU and UK, with more than 347,108 deaths
worldwide3. Figures 1 and 2 show the current set of data
of the pandemic, with a special attention to China and
Italy. With the great efforts mostly based on strict con-
tainment measures, China has successfully emerged out of
the first wave of the epidemic at the beginning of April
2020, when the social order slowly returned to the norms.
Although different precautionary measures have been
taken at national level in the EU to limit and to monitor
the entrance of potential COVID-19 cases from China,
the first symptomatic cases have been reported before the
end of February in a number of EU countries including
Italy, Spain, Germany, and, just weeks later, UK. In this
context, Italy is one of the first and hardest hit country in
Europe, with over 219,000 cases and 30,500 deaths
reported.
The SARS-CoV-2 virus is structurally and functionally
closely related to the other coronaviruses causing Middle-
East respiratory syndrome coronavirus (MERS-CoV) and
severe acute respiratory syndrome coronavirus (SARS-
CoV). In particular, it is the external protein of the virus,
the glycoprotein spike (S) (Fig. 3), that is able to bind and
recognize the human receptor angiotensin-converting
enzyme 2 (ACE2), primed by the transmembrane pro-
tease serine type 2 (TMPRSS2), and/or CD147 (extra-
cellular matrix metalloproteinase inducer), and therefore
infect the host cells4–6 (Fig. 4). The crucial recent eluci-
dation of these structures at the fine biochemical level will
pave the way for future potential therapeutic interven-
tions. The viral genomic sequences assembled from
samples in Shanghai together with uploaded sequences in
the Global Initiative on Sharing All Influenza Data
(GISAID, www.gisaid.org) also showed a stable evolution
(H.L., unpublished data). Based on current data, SARS-
CoV-2 seems to have a mutation rate of around 25
mutations per year, which is much lower than that of
influenza virus7. Therefore, development of effective long-
lasting vaccines against the virus is possible.
In this review, we update the latest clinical character-
istics, diagnosis strategies, as well as clinical management
of the COVID-19 in China. We decided to compare the
data of China and Italy because these were the first two
countries hit by the pandemic at the highest level;
therefore, this experience may be of relevance for other
countries. Being the first two countries we feel appro-
priate to evaluate the evolution of the disease as well as
the early result of the treatment, in order to offer a dif-
ferent baseline to other countries. It is also interesting to
compare two countries, with a very significant difference
in population, where the morbidity and mortality has been
so different and unrelated to the size of the country.
Clinical and laboratory characteristics
The COVID-19 clinical features in adults are reported
in Table 1. The median incubation period (interquartile
range, 2–7) is around 4 days8. Fever is one of the most
common symptoms occurring in as high as 98% of the
patients reported1. A relatively high proportion of patients
develop fever although they are afebrile at the onset of the
disease8. The predominant symptom is dry cough,
reported in around 60% of the patients8. Gastrointestinal
symptoms including nausea, vomiting, and diarrhea are
less frequently developed, with an incidence lower than
10% of the patients1,8,9. Other symptoms including rhi-
norrhoea, sore throat, fatigue, dyspnea, muscle weakness,
dizziness, and headache are also often reported in
COVID-19 patients.
Lymphopenia and leukopenia has been observed in the
majority of patients, together with elevated level of
C-reactive protein, lactate dehydrogenase, D-Dimers, and
other inflammatory biomarkers, including tumor
necrosis factor-α (TNFα), interleukin-1β (IL-1β), IL-6,
granulocyte-macrophage colony-stimulating factor as well
as IL-10 (refs. 1,8–11). T cell exhaustion, especially CD4+
T cells is a hall marker of infected patients, paralleling
with the severity of the illness8.
The vast majority only suffered from mild symptoms.
However, the early report in Chinese involving 44,672
confirmed cases, 81% patients are mild cases, and 14.8%
patients are severe, while only 5% patients are critically
ill12,13. Numbers of comorbidities were associated with
poorer outcomes14. The median onset time from early
symptoms to dyspnea is around 7 days, while acute
respiratory distress syndrome (ARDS) developed around
9 days1. The median days of fever in survivals is
10–12 days and cough persisted for 19 days8,10. The
severity of the diseases varies in different age groups, with
older patients at higher risk of mortality compared to
those of younger age. In children, the symptoms are often
mild and the prognosis of pediatric patients is largely
more favorable than adults15. Table 1 compares the major
characteristics of COVID-19 in China versus Italy.
Patients in Italy were more older compared to patients in
China, with more numbers of comorbidities. The number
and severity of these co-morbidity has been a major factor
influencing the outcome; this was particularly evident
where the virus diffused into old pension homes. Indeed,
while the mortality was 3.1% in Italy, with the exception of
the Milan area (Fig. 1b) where it was 6.8%, within the
residences for old people it peaked to 24% (https://www.
epicentro.iss.it/). In this case, out of 3859 death, only 133
were confirmed by swabs, while 1310 had all symptoms
but they were not tested. Disease severity was strongly age
dependent, primarily due to the presence of comorbid-
ities. Therefore, the proportions of severe and critical
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Fig. 1 Spread and dynamics of the COVID-19 pandemic. Spread and dynamics of the COVID-19 pandemic on a worldwide scale (a), source
Worldmeter (www.worldmeters.info), and on Italy (b), modified with permission from PNAS USA, 2020. https://doi.org/10.1073/pnas.2004978117.
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Fig. 2 COVID-19 pandemic in different countries. Cumulative numbers of cases (a) and deaths (b) in China, European, and the United States.
Distributions of the cases (c). The inset in panel a reports the new cases in Italy as to 10 May, showing a drastic reduction on morbidity. Source
Worldmeter (www.worldmeters.info) and Protezione Civile (http://www.protezionecivile.gov.it/attivita-rischi/rischio-sanitario/emergenze/
coronavirus). Distribution of laboratory confirmed cases of COVID-19 in the Italy, China, and the USA, as of 10 May 2020.
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patients in Italy were higher than that in China, partially
leading to a higher mortality.
Asymptomatic patients
A proportion of the patients showed no symptoms at
enrollment as they were at very early stage of the diseases.
These patients could either recover without developing
symptom or would continue to develop symptoms.
However, the former group of patients never have any
symptoms or signs, but their respiratory tract specimens
are PCR positive for the virus. The exact number of the
proportion of asymptomatic patients requires longitudinal
study with repeated PCR tests. In a study that followed 13
patients in Wuhan, China, 31% of them never developed
symptoms16. In another study performed on the Diamond
Princess cruise ship, repeated PCR testing of 3711 quar-
antined passengers and crew members showed that
asymptomatic proportion is around 18%17. More recently,
the proportion of infected people have mild or asympto-
matic were estimated to represent some 60% of all
infections18. Notably, asymptomatic and symptomatic
patients show comparable viral load, suggesting that these
patients have strong transmission potentials19. Indeed,
viral transmission from asymptomatic carriers have been
reported20. In a recent study from China, Chen et al.
followed up 2147 close contactors of 191 patients
(161 symptomatic and 30 asymptomatic). They found that
the infection rates of transmission rate in symptomatic
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Fig. 3 SARS-Cov spike glycoprotein. The coronavirus SARS-Cov-2 spike (S) glycoprotein is responsible for viral entry into the cell and it is the major
target of antibody recognition. SARS-Cov-2 S is an ectodomain trimer. All three coronaviruses causing severe acuter respiratory syndrome coronavirus
(SARS-Cov), Middle-East respiratory syndrome coronavirus (MERS-CoV), and SARS-CoV-2 are closely related and contain a transmembrane spike, S,
glycoprotein with two functional subunits able to bind the cells (S1 subunit) and responsible for fusion of the viral and cellular membrane
(S2 subunit). SARS-Cov-2 spike S shows a closed and an open conformation (depicted), where only the closed conformation binds the human ACE2
receptor-binding domain. The structure shown was obtained by Cryo-EM (closed: PBD= 6VXX at 2.8 Å resolution; open: PBD= 6VYB at 3.2 Å
resolution) was released on 11 March 2020 from Walls et al.4.
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cases was 6.3% comparing with 4.1% in asymptomatic
patients, indicating the importance of identification and
isolation of asymptomatic patients in the effort of con-
tainment the spread of the virus21. Importantly, for large-
scale screening, antibody testing should be combined with
PCR to avoid asymptomatic viral spreading.
Diagnosis of COVID-19
Nucleic acid tests
The definitive diagnosis of the disease relies on the
identification of viral genomic RNA using either PCR-
based technology or deep sequencing. The detailed PCR-
based methods have been reviewed elsewhere22. The
presence of sufficient viral genome for amplification at the
site of sample collection is the precondition of the tests.
Therefore, collecting the appropriate specimen from
patients at the right time using the adequate protocol is a
key in diagnosis of the infection. Besides in the respiratory
tract, viral particles have also been detected in the blood,
lacrimal fluid, urine, and feces23,24. In a recent study, the
virus was detected in different types of samples, such as
bronchoalveolar lavage fluid (BALF) (93% positive),
pharyngeal swabs (32%), fibrobronchoscope brush (46%),
nasal swabs (63%), feces (29%), sputum (72%), and blood
(1%)24. However, the samples were not from the same
patients at the same time, making it impossible to com-
pare the sensitivity of the PCR test in different types of
specimens.
As a viral pneumonia, respiratory tract specimens from
COVID-19 patients are first of choice to collect for the
detection of viral nuclear acid. Collecting and testing
upper respiratory specimens would be ideal considering
the feasibility in clinical practice. Nasopharyngeal and
oropharyngeal swab are the optimal manner for swab viral
testing. These samples can even be collected by patients
themselves. Self-collected saliva specimens had been test
and yield positive results in most of the infected patients,
indicating that it is an adequate non-invasive test for
monitoring and diagnosis of the infections25. To increase
the sensitivity of the diagnosis, it is preferably to collect
multiple different types of specimens. However, negative
naso-oro-pharyngeal swab could not completely rule out
COVID-9 (ref. 26). Cases with repeated negative PCR for
the virus in naso-oro-pharyngeal tests but positive in
bronchoalveolar lavage fluid (BALF) samples have been
reported26. It is therefore necessary to collect BALF via
bronchoscopy in patients highly suspected of COVID-19,
although this procedure could significantly increase the
safety danger to healthcare personnel through the crea-
tion of aerosol droplets. This is an important issue,
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Fig. 4 ACE2 receptor binding the SARS-Cov-2 virus. The initial step of SARS-Cov-2 viral entry during the infection is the binding of the viral
trimeric spike protein (cleaved into S1 and S2 subunits, the former of which contains the receptor-binding domain, RBD) to the dimeric human
receptor angiotensin-converting enzyme 2 (ACE2) which is here represented in the complex with the membrane protein that it chaperones, BoAT1.
ACE2 is formed by an N-terminal peptidase domain (PD) and the C-terminal collectrin-like domain (CLD). ACE2 shows a closed and an open
(depicted) conformation at the PD level of contact; however, only the closed conformation binds the RBD of SARS-Cov-2. The structure shown was
obtained by Cryo-EM at 2.9 Å resolution (PBD= 6M17) was released on 11 March 2020 from Yan et al.6.
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Table 1 Comparison of clinical data in china versus Italy.
Chinaa
(N= 44,672)
Chinab
(N= 113
deaths)
Italyc
(N= 127,790)
Italyd (N= 1591 ICU
patients)
Italye (N= 14,860 deaths)
Age (median,
interquartile range)
N/A 68 (62–77) 62 (IQR, N/A) 63 (56–70) 80 (73–85)
Age (group)
0–18 965 (2.2%) N/A 2045 (1.6%) N/A 1(0)
19–50 19,970 (44.7%) N/A 46,132 (36.1%) N/A 177 (1.1%)
51–70 18,591 (41.6%) N/A 45,493 (35.6%) N/A 2291 (15.4)
>70 5326 (11.9%) N/A 34,120 (26.7%) N/A 12,390 (83.4%)
Gender
Male 22,981(51.4%) 83 (73%) 67,601 (52.9%) 1304 (82%) 10,062 (67.7%)
Female 21691 (48.6%) 30 (27%) 60,189 (47.1%) 287 (18%) 4798 (32.3%)
Symptoms
Asymptomatic 36160 (80.9%) N/A 4169 (8.5%) N/A N/A
Paucisymptomatic N/A 7945 (16.2%) N/A N/A
Mild symptoms N/A 18,832 (38.4%) N/A N/A
Severe symptoms 6168 (13.8%) N/A 9416 (19.2%) N/A N/A
Critical 2087 (4.7%) N/A 1324 (2.7%) N/A N/A
Not specified 257 (0.6%) N/A 7356 (15.0%) N/A N/A
Sign symptoms
Fever N/A 104 (92%) N/A N/A 76.0%f
Dyspnea N/A 70 (62%) N/A N/A 72%f
Cough N/A 79 (70%) N/A N/A 39%f
Fatigue N/A 64 (57%) N/A N/A N/A
Diarrhea N/A 27 (24%) N/A N/A 6%f
Dizziness and headache N/A 21 (19%) N/A N/A N/A
Co-morbidity
Cardiovascular and
cerebrovascular diseases
3556 (17.0%) 70 (61.9%) N/A 223 (21%) (hypertension
509 (49%)
Ischemic heart disease: 363
(28.1%); atrial fibrillation: 290
(22.5%); heart failure: 207
(16.0%); stroke: 144 (11.2%);
hypertension: 911 (70.6%)
Endocrine system diseases 1102 (5.3%) 24 (21.2%) N/A Diabetes: 180 (17%);
hypercholesterolemia:
188 (18%)
Type 2 diabetes: 409 (31.7%);
obesity: 129 (10.0%)
Digestive system diseases N/A 1 (0.9%) N/A N/A N/A
Respiratory system diseases 511 (2.4%) 11 (9.7%) N/A COPD^: 42 (4%) COPD 234 (18.1%)
Chronic hepatitis B virus
infection
N/A 5 (4.4%) N/A Chronic liver disease: 28 (3%) Chronic liver disease: 49 (3.8%)
Chronic kidney disease N/A 4(3.5%) N/A 36 (3%) 298 (23.1%)
Malignant tumor 107 (0.5%) 1 (0.4%) N/A 81 (8%) 217 (16.8%)
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considering that in Italy alone, over 170 doctors have died
so far!
As soon as possible on the earliest days of symptoms,
swabs should be collected from the upper respiratory tract.
Recent studies showed that the viral load in the upper
airway samples peaks within the first week and the virus
was cleared at a median of 9 days from infection25–27.
Similar shedding patterns were seen for MERS-CoV and
SARS-CoV: RNA swab positivity was evident within the
first week of MERS infection, while it peaked at 7–10 days
after symptom onset in SARS. The dynamic of SARS-
CoV-2 shedding in the lower respiratory tract specimens is
still unclear. In MERS, MERS-CoV viral load peaked
between week 2 and 3 in lower airways specimens, while
the SARS-CoV RNA-positive rates in lower airways sam-
ples remained higher for 3 weeks after beginning of illness
in SARS28,29. It is likely that SARS-CoV-2 also shares a
comparable viral shedding pattern in the lower respiratory
tract specimens. This may explain why some patients
progressed despite PCR turned negative in the upper
respiratory specimens8.
Despite the high accuracy of the PCR tests, these nucleic
acid tests highly depend on the procedures of sample
collecting, in addition to high labor and time costing. The
test protocol is generally expensive and complex, and
therefore difficult to be broadly applied in resource lim-
ited locations. Transferring samples to a central labora-
tory not only decrease the accuracy of the tests either by
sample decay due to incorrect storage or contamination
but also further delay the test results. A false-positive test
could result in an unnecessary quarantine and therapy
while a false-negative diagnosis may allow infected
patients to spread the virus. Therefore, other methods are
also needed to serve as a supplement. Most importantly,
as the virus spreading many healthcare personnel have
caused wanton community transmission before correct
testing allowed isolation and tracking. Therefore, tests
that are able to be scaled up quickly are urgently needed.
Serological tests
Serological assays detect both SARS-CoV-2-specific
antibodies IgM, IgA, and IgG, which are produced both
at the early and later phases of the disease, respectively.
Unlike PCR tests, antibody tests could be less accurate
and require longer time to be established as routine tests.
However, serological tests are portable, user-friendly, and
can produce results in 10–30min at least at the qualitative
level. Moreover, they request very limited sample volume:
one drop of blood from a pinprick is sufficient to detect
the antibodies. Therefore, they can be established as
decentralized point-of-care (POC) tests. In a cohort
comprised of 82 confirmed and 58 probable (qPCR test is
negative despite other indications of COVID-19 including
symptoms and epidemiology) COVID-19 cases, the posi-
tive detection rate is extremely high (98.6%) when PCR is
performed in conjunction with IgM ELISA for every
patient as compared to qPCR analysis alone (51.9%)30.
Therefore, the serological tests could be used together
with nuclei acid detection to increase the sensitivity of
tests. In China, some of these kits have received fast-track
approval from the National Medical Products Adminis-
tration (NMPA). In the USA, only one serological test has
been approved by the date of submission. These tests are
of good accuracy with sensitivity range from 87.3% to
97.2% and specificity range from 95.6% to 100%. The
detailed serological tests has been reviewed elsewhere31,32.
However, the sensitivity of serological assays is influ-
enced by both the time of sample collection as well as
human immune response status. In the study by Guo
et al., as high as 22.0% (18/82) of the PCR confirmed cases
were found to be negative by an IgM antibody tests. Most
of the COVID-19 patients were able to generate antibody
Table 1 continued
Chinaa
(N= 44,672)
Chinab
(N= 113
deaths)
Italyc
(N= 127,790)
Italyd (N= 1591 ICU
patients)
Italye (N= 14,860 deaths)
Dementia N/A N/A N/A N/A 203 (15.7%)
Autoimmune diseases N/A 1 (0.4%) N/A N/A 40 (3.1%)
Median days from symptom
onset to date of diagnosis
(median, interquartile range)
N/A 10 (7–13) 5.1 (95%
confidential
intervals, 4.5–5.8)f
N/A N/A
N/A not available.
aSee ref. 12 (A summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention).
bSee ref. 90.
cSee ref. https://www.epicentro.iss.it/coronavirus/bollettino/Bollettino-sorveglianza-integrata-COVID-19_6-aprile-2020.pdf.
dSee ref. 91.
eSee ref. https://www.epicentro.iss.it/coronavirus/bollettino/Report-COVID-2019_6_aprile.pdf
fAbsolute number not available.
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within 10 days after symptoms onset. Suspected patients
who tested IgM/IgG negative in their early phase of dis-
ease could have repeated IgM/IgG tests30, if nucleic acid
tests are not available. In addition, the serological assays
can also provide historic information about viral expo-
sure, which are important for epidemiology studies.
Interestingly, early presence of IgA might be protective
and a surrogate marker of good outcome, detecting of
which may help identifying patients warrant medical
attention33,34. Therefore, the speed and versatility of ser-
ological assays make them invaluable tools for COVID-19
diagnosis and efforts to produce antibody detection kits
on a huge scale have begun to be produced31. Clearly,
serological determination is the future both for diagnostic
as well for epidemiological purposed.
Computer tomography
The COVID-19 patients presented some typical char-
acteristics on the chest computed tomography (CT)
image. Ground-glass opacity was the most frequent, with
subsequent consolidations, air bronchogram, irregular or
smooth interlobular septal thickening, and thickening of
the nearby pleura, with predominantly lower and per-
ipheral lobe involvement9,35 (Fig. 5). A recent study by Ai
et al.36 involved 1014 patients in China reported that the
sensitivity of toracic CT in suggesting COVID-19 was
97%. In the early February, 2020, some experts in China
suggested CT as one of the best clinical diagnostic criteria
together with epidemiology, clinical, and laboratory
characteristics to pronounce the clinically diagnosed
COVID-19 when PCR tests were not available. None-
theless, not all the patients had the typical chest CT
images (e.g., asymptomatic COVID-19 cases). Absence of
CT or radiographic abnormality was observed in as high
as 17.9% patients with non-severe disease and in 2.9%
cases with severe disease9. Notably, the typical CT image
sometimes could not distinguish COVID-19 from influ-
enza infections. In the study by Ai et al.36, 75% of patients
with negative RT-PCR swabs showed positive thoracic
CT results. Given that the misdiagnosis of COVID-19 in
cases has grave consequences as mentioned above, CT
should not be used alone to make the diagnosis of
COVID-19.
Clinical management
At present, there are no specific treatment with con-
firmed efficacy for COVID-19 and the therapeutic pro-
tocol is as per best supportive care for any respiratory
disease. However, both antivirals and immune modulators
warrant further investigation especially considering the
biphasic pattern of immune responses during the diseases
course8. Several drugs with potential antiviral activities
are under active investigation. More recently, the WHO
also launched multinational trial to validate four drugs
especially in combinations, including ritonavir/lopinavir,
lopinavir and ritonavir with interferon-beta, chloroquine
and/or remdesivir. Several clinical trials, over 1673, have
been registered worldwide and are listed at www.
clinicaltrials.gov (specifically see: https://clinicaltrials.
gov/ct2/results?cond=covid-19). A selected clinical trials
with possible significance are listed in Table 2.
Chloroquine and hydroxychloroquine
Chloroquine (CQ) and its related drug hydroxy-
chloroquine (HCQ), both of which are well-known for
their effectiveness in treating malarial and autoimmune
diseases, have also recently been repurposed to treat
COVID-19. In vitro studies showed that both CQ and
HCQ were of excellent antiviral activity against SAR-CoV-
2 with an EC50 of 1.13 and 0.72 μM, respectively, which are
reachable in humans when admitted37,38. In fact, CQ and
HCQ have been shown to have antiviral activities to dif-
ferent viruses including dengue virus, chikungunya virus,
Ebola virus, etc. Any effect found has been limited to
in vitro culture. There is no in vivo efficacy reported. Many
randomized controlled trials are undergoing to evaluate
the efficacy of CQ and HCQ in treating or even in pre-
venting COVID-19. We completed the first randomized,
control, open-label trial to evaluate the antiviral activity
and safety of HCQ in treating COVID-19. Unfortunately,
in this pilot study with 30 patients, we failed to observe any
benefit of adding HCQ on top of the standard of care39.
However, more recently, another study from France
showed that HCQ was effective against SARS-CoV-2,
especially when combined with azithromycin40. These two
studies were both limited by the small sample size. The U.
S. Food and Drug Administration (FDA) has launched a
trial to investigate the effectiveness of CQ in COVID-19
(https://www.fda.gov/news-events/press-announcements/
coronavirus-covid-19-update-fda-continues-facilitate-
development-treatments). More recently, a study was
completed in Renmin Hospital of Wuhan University with
62 COVID-19 patients41. This study was based on a
follow-up survey, showing that none of the 80 SLE patients
who took long-term oral HCQ showed SARS-CoV-2
infection or appeared to have related symptoms. The study
found that the cough remission time and the body tem-
perature recovery time were strongly reduced in the HCQ
treatment group. Over 80% (25 of 31) of the patients in
HCQ treatment group showed improvement in pneumo-
nia compared with the matched controls (54.8%, 17 of 31).
Importantly, 61.3% of patients in the HCQ treated group
showed significant pneumonia absorption. Among the 31
patients in the HCQ treated group, 2 of them had mild
adverse reactions, one developed rash and one patient
experienced a headache. Clearly, these results warrant
further randomized, controlled studies. Remarkably, HCQ
is a strong immune modulator and has been used widely
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for the therapy of systemic lupus erythematosus or rheu-
matoid arthritis. It exerts its effects likely through inhi-
biting the secretion of IL-1β, TNF-α, and IL-6 from
macrophages/monocytes, which are a key cell population
in ARDS development in COVID-19 patients. Thus HCQ
application should be limited to patients who have started
to develop or already developed ARDS. Since immune
response at the early stage is critical for controlling
infection and the antiviral effect of HCQ is still in ques-
tion. In addition, the safety of CQ/HCQ should also be
taken into consideration. CQ/HCQ are associated with
cardiac arrhythmias, hypoglycemia, and neuropsychiatric
effects42. Therefore, these compounds should not be
recommended for mild patients or for prevention purpose,
at least for now.
Moreover, the combination of HCQ with antibiotic
drug azithromycin has been reported to have added
benefit. Since azithromycin is known to reversibly binds
to the 50S ribosomal subunit of the 70S ribosome to
inhibit the translocation step of protein synthesis, whether
it has antiviral effect is not known. It is also not known
whether azithromycin synergize with HCQ to provide
better antiviral activity. A recent prospective study failed
to find antiviral activity or clinical benefit of this combi-
nation for the treatment of our hospitalized patients with
severe COVID-19 (ref. 43). Further investigations are
needed. Needless to say, at late stage of ARDS, controlling
secondary bacterial infection should not take lightly.
In addition to treatment, CQ/HCQ has also been sug-
gested for prophylaxis of COVID-19 (ref. 44). When
Fig. 5 Computer tomography image of COVID-19. Early (a) and late stage of COVID-19 (b) computer tomography of the lung showing a diffuse
interstitial pneumonia.
Chen et al. Cell Death and Disease          (2020) 11:438 Page 10 of 17
Official journal of the Cell Death Differentiation Association
awaiting more evidence from clinical trials, we currently
do not recommend use CQ/HCQ for prophylaxis of
COVID-19.
Lopinavir/ritonavir
Lopinavir/ritonavir (LPV/r) is a mix of protease inhi-
bitors commonly used for the therapy of HIV-1 infection,
often known as highly active anti-retroviral therapy
(HAART). The combination of LPV/r with additional
ribavirin was reported to be able to reduce the risk of
acute respiratory distress syndrome and mortality in
SARS patients45. Meanwhile, LPV/r and interferon β were
found to have better efficacy compared with controls for
MERS-CoV infection in animal experiments and case
reports46–49. LPV/r was therefore repurposed to treat
COVID-19, as SARS-CoV-2 was genetically close to
MERS-CoV and SARS-CoV. However, in a retrospective
study with 134 patients (more than 95% patients were
mild cases), we recently find that administration of LPV/r
along with interferon alpha inhaling was not associated
with faster virological clearance or clinical improve-
ment50. More recently, a randomized, controlled study
conducted in Wuhan, China also failed to identify bene-
ficial effect of LPV/r beyond standard therapy in hospi-
talized patients with severe Covid-19 (ref. 51). More
importantly, in another randomized control study with a
small sample size, LPV/r was associated with adverse
events not only failed to show antiviral activity52. Based on
these available data, it is likely that LPV/r and other HIV-
1 protease inhibitors including darunavir are not effective
in treating COVID-19.
Remdesivir
Another promising drug is the adenosine analog
remdesivir (GS-5734) that is incorporated into nascent
viral RNA chains where it causes a pre-mature termina-
tion53. Remdesivir is also an experimental drug that was
generated for the therapy of the Ebola viral infection.
Notably, remdesivir has shown antiviral efficacy in treat-
ing SARS and MERS in animal models54,55. Recently,
in vitro study showed that, in Vero E6 cells, EC90 value of
remdesivir versus SARS-CoV-2 was 1.76 μM, indicating
its active concentration could likely be obtained in vivo37.
In SARS-CoV-2-infected rhesus macaques, therapeutic
remdesivir treatment was found to reduce viral load when
given early56. In the USA, the first COVID-19 patient was
treated with intravenous remdesivir and recovered57. In a
recent cohort of hospitalized patients with severe COVID-
19, compassionate-use remdesivir was associated with
clinical improvement in 36 of 53 patients (68%)58. In a
randomized, double-blind, placebo-controlled, multi-
centre trial, remdesivir use was not associated with a
difference in time to clinical improvement. However,
when given with symptom duration of 10 days or less,
Table 2 A selected examples of significant clinical trials.
Conditions Numbers of enrollment
(estimated)
Results Reference/trials
Hydroxychloroquine Mild 30 Negative 39
Hydroxychloroquine Mild/severe 62 Positive 41
Hydroxychloroquine Symptomatic disease 510 Ongoing https://clinicaltrials.gov/ct2/show/NCT04332991
Hydroxychloroquine Prevention 40,000 Ongoing https://clinicaltrials.gov/ct2/show/NCT04303507
Lopinavir/ritonavir Severe 199 Negative 51
Remdesivir Mild/Moderate 308 Ongoing https://clinicaltrials.gov/ct2/show/NCT04252664
Remdesivir Severe 453 Negative 59
Remdesivir Severe 2400 Ongoing https://clinicaltrials.gov/ct2/show/NCT04292899
Remdesivir Moderate 1600 Ongoing https://clinicaltrials.gov/ct2/show/NCT04292730
Remdesivir Moderate/Severe 800 Ongoing https://clinicaltrials.gov/ct2/show/NCT04280705
Dexamethasone Severe 200 Ongoing https://clinicaltrials.gov/ct2/show/NCT04325061
Tocilizumab(IL-6 inhibitor) Severe 20 Positive 84
Tocilizumab Mild/Severe 188 Ongoing http://www.chictr.org.cn/showprojen.aspx?
proj=49409
Anakinra (IL-1 inhibitor) Mild/Severe 342 Ongoing https://clinicaltrials.gov/ct2/show/NCT04330638
Baricitinib (JAK inhibitor) Mild 80 Ongoing https://clinicaltrials.gov/ct2/show/NCT04340232
Convalescent plasma Severe 10 Positive 63
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patients receiving remdesivir had a numerically faster
time to clinical improvement than those receiving pla-
cebo59. This study was underpowered as it failed to enroll
the estimated number of participants. However, pre-
liminary results from another NIH clinical trial shows
remdesivir was associated with 31% faster time to recov-
ery from advanced COVID-19 and a marginal survival
benefit, with a mortality rate of 8.0% for the group
receiving remdesivir versus 11.6% for the placebo group
(p= 0.059)60. As an emergent therapeutic approach, FDA
recently issued emergency-use authorization for remde-
sivir to treat hospitalized patients with severe Covid-19.
Several clinical trials are currently ongoing, and the
results regarding effectiveness and safety are still being
awaited for.
Camostat
The recent work elucidating the structure and mole-
cular mechanism of viral entry4–6 showed the specificity
of the serine protease inhibitor camostat mesylate as an
active compond against TMPRSS2 which is required for
viral infection. Camostat mesylate seems rather specific,
since SARS-Cov-2 infection requires TMPRSS2 for the
priming of the viral S protein. Clinical trial of camostat
mesylate or its derivatives are therefore required4–6.
Ivermectin
The recent work on the FDA-approved anti-parasitic
compound ivermectin seems extremely powerful even
though so far it is only in vitro61. Clinical trial to repur-
pose this approved drug is urgently needed.
Convalescent plasma
Convalescent plasma is also a potentially promising
strategy to treat COVID-19. In a recent case study, the
clinical status of all the five critically ill COVID-19
patients receiving convalescent plasma showed a sig-
nificant improvement within 1 week following the infu-
sion, normalization of body temperature, as well as scores
of the sequential organ failure assessment. Moreover,
within 1–12 days following the infusion, the neutralizing
antibody titers of the patients improved and the respira-
tory samples tested negative for SARS-CoV-2 (ref. 62). In
another study of 10 severe cases, the viral titers were
undetectable following the infusion in seven patients who
had previously high viremia63. Previous studies on other
respiratory viral diseases provided some evidences on the
efficacy of convalescent plasma on treating severe and
critical viral diseases. Several studies in SARS patients
reported that the use of convalescent plasma was linked to
reduced hospital stay and reduced mortality64,65. Clinical
trials also showed that in patients with severe H1N1
influenza A, in the 2009 pandemic, therapy with con-
valescent plasma from patients who recovered, especially
within 5 days of symptom onset, resulted in a lower viral
load and lower mortality66,67. Subsequent analysis showed
that the mortality of patients with severe acute viral
respiratory infections was reduced after therapy with
convalescent plasma, while absence of adverse events or
complications were observed68.
Nevertheless, there are still issues we need to tackle.
The first question is when to collect plasma from recov-
ered COVID-19 patients. Recent work by To et al.25
showed that, day 10 after symptom onset, both IgG and
IgM antibodies increased in the majority of patients, while
seroconversion was observed within the first 3 weeks.
Importantly, the anti-SARS-CoV-2 IgG and IgM antibody
levels against the internal nucleoprotein and the spike S1
domain correlated with neutralizing activity. Therefore, it
would be ideally to collect convalescent plasma from week
3 after symptom onset. Despite hundreds of patients had
recovered from COVID-19, eligible convalescent plasma
is quite limited as the donors have to pass physical and
laboratory examination, and plasma should also be tested
for SARS-CoV-2 nuclear acid, HIV-1, HBV, and HCV, as
well as antibody titers, to list a few. The second question is
deciding which patients and when should receive the
convalescent plasma. The effects of convalescent plasma
are difficult to observed when used in critical patients
with multiple organ failure, as the viral load in this kind of
population is quite high. Hence it is preferably to use
convalescent plasma in mild patients whose diseases was
deteriorating in their early phase of diseases. Normally, in
COVID-19, the viral load peaked at the first week of ill-
ness, and then slowly decline during the subsequent
week25. Accordingly, in principle, the most effective to
administer the convalescent plasma is at the early phases
of the disease. The biggest challenge is that it is quite
difficult to identify which patient will deteriorate in the
early stage. Several risk factors including older age, male,
multiple comorbidities, elevated IL-6, and elevation in D-
dimer levels that are associated with bad outcomes may be
used as surrogate markers10. Provided further studies
demonstrate its efficacy in appropriately selected patients,
the next step would be the production of humanized
antibody at biotechnological level.
Cytokine storm syndromes and its management
It is still not clear why some patients progressed while
others recovered, which underlying biological marker
would be of essential benefit for the management of the
patients. Indeed, several reports are still in wide contrast.
The duration from onset of symptoms to viral clearance is
significantly longer in severe and critical ill SARS-CoV-2-
infected patients compared with that in the mild cases48.
Notably, elevated level of a bundle of pro-inflammatory
cytokines was observed in severe and critical ill patients,
which include interferon-γ inducible protein 10,
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interleukin (IL)−2, IL-7, IL-6, macrophage inflammatory
protein 1-α, granulocyte-colony stimulating factor, tumor
necrosis factor-α, and monocyte chemoattractant protein
1 (refs. 1,11). More importantly, in a recent retrospective,
multicenter study conducted in Wuhan, China, increased
plasma levels of ferritin and IL-6 were identified as pre-
dictors of fatality69. Therefore, it is reasonable to speculate
that the persistence of SARS-CoV-2 induced excessive
and abnormal non-effective response that leads to organ
dysfunction70,71. The inflammation persists in some
patients despite the viral clearance8,72. Taken together,
these evidences support the importance of dampening the
overly exuberant immune responses besides antiviral
therapy in reducing the mortality73, as we discussed
previously74.
The dual role of the immune system74 is crucial and still
under investigation to clarify the strength and duration of
the immune response both for the perspective of post-
infection protection and re-infection, but also, and most
relevant, for the efficacy of the future vaccine.
Many therapeutic drugs are now available to suppress
immune response. Among these drugs, corticosteroid is
the most widely used. However, the utility of corticos-
teroid in treating COVID-19 is still debating. Most
guidelines on COVID-19 currently do not recommend
application of corticosteroid as data are very limited. On
the one hand, corticosteroid apparently delay clearance of
MERS-CoV from respiratory tract and SARS-CoV from
blood, respectively75,76. On the other hand, clinical studies
reported that low or physiologic dose of corticosteroids
treatment could have clinical benefits to earlier reversal of
shock, shorter stay in ICU, and less mechanical ventilation
although it did not reduce mortality caused by primary
lung infections77. In patients with severe H1N1-illness,
low dose of corticosteroids also lead to lower mortality78.
Several clinical trials are now in progress to evaluate the
benefit of corticosteroids in treating COVID-19. When
waiting for the results, proper use of low-dose corticos-
teroids at the right time might has survival advantages for
severe/critically ill patients with COVID-1979.
CQ and HCQ might also be able to modulate the over
activated immune response. They alter the pH and disrupt
autophagy and lysosomal activity, destabilize membrane,
and disrupt signaling pathways and transcriptional activ-
ity, subsequently inhibiting antigen presentation, immune
activation, MHC class II expression, reduced pro-
inflammatory cytokines, and deregulation of co-
stimulatory molecules80. However, whether its suppres-
sion on the immune response may lead to delay of SARS-
CoV-2 clearance is still unclear. In some viral diseases
including HIV infection, HCQ administration was asso-
ciated with increased viral replication81.
Other therapeutic drugs that under investigation
include the IL-1 inhibitor, IL-6 inhibitor, and JAK-STAT
signal pathway inhibitors. Treatment with IL-1 blockade,
in a phase 3 randomized controlled trial in sepsis patients
with macrophage activation syndrome, resulted in a
drastic improvement in the 28-day survival rate82. IL-6
inhibitor, which was used as a treatment for rheumatoid
arthritis and CRS associated with CAR-T cell therapies for
cancer, has now repurposed to treating COVID-19 in
severe and critical patients as recommended by a Chinese
government guideline83. Interestingly, preliminary results
from the two available IL-6 inhibitors (tocilizumab and
sarilumab) with different study population showed con-
trasting results, indicating that choose appropriate
population is essential for anti-IL-6 treatment84.
Upstream of that, the treatment with inhibitors of TNF-β
could be applied, but there are no data available so far.
Inhibition of Janus kinase (JAK) in COVID-19 patients
target both inflammation and cellular viral entry85.
Recently, a pilot study suggest that JAK inhibitor is active,
well tolerated in patients with secondary hemophagocytic
lymphohistiocytosis indicating these drug maybe apply to
COVID-19 treatment86.
Discharge and follow-up
Most of the patients can be discharged after archive
negative PCR results from two continues respiratory tract
specimens, together with defervescence and improvement
in radiological image83. The median duration from
symptoms onset to the first negative PCR results was
12 days in non-intensive care units group, as compared
with 26 days in the ICU groups. In critical ill patients, the
time of viral shedding can be as long as 52 days. The
slower clearance of the virus in the critical ill patients
might be explained by both higher viral load at baseline
and impaired immune responses. In a recent study, the
mean SARS-CoV-2 viral load of critical ill patients was
circa 60 times higher than that of moderate cases, indi-
cating that higher viral loads is linked to severe clinical
outcomes87. In addition, the critical ill patients also
showed impaired immunity characterized by lymphopenia
and lower CD4 T cell counts, which were associated with
the duration of viral shedding8,27. Our cohort in Shanghai
showed the median duration of hospital stay was
16 days8,12,20. However, studies have shown that viral
shedding is longer in the feces than in the respiratory
tract specimens23. More importantly, SARS-CoV-2 iso-
lated from feces was of replicability. Despite the uncer-
tainty of transmissibility of SARS-CoV-2 in feces, it
indeed challenged the quarantine given the high infec-
tivity of the virus. Notably, PCR turned to be positive
again in a small proportion of patients, although no
infection cases of these close contactors had been
reported. Therefore, we recommend that patients
recovered and discharged should be continue to quar-
antine for another 14 days.
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Preventive measures to minimize recurrence of
epidemics
Some models had attempted to quantify the impact of
different strategies to prevent the potential spread of
COVID-19 that should be carefully considered for policy
makers in planning the next steps. In interpreting these
models, we should keep in mind that they assume that
variations in the replication rate of SARS-CoV-2 - an
evaluation of transmission - are an immediate response to
the interventions implemented, rather than broader gra-
dual behavioral changes. While first models, however,
addressed a set of variables before locking down, on the
number of cases and avoided deaths, more recently new
models are struggling to predict the effect of gradual
normalization of public life of different strategies. In fact,
despite the fact that in Italy, Spain, and Germany the
increase in number of new SARS-CoV-2 infections has
been reducing in recent days, the political measures (on
early April 2020) for restricting contacts at national level
continue to be in place. In a recent report from the
Leopoldina Nationale Akademia der Wissenchaften88,
authors concluded that in addition to the current
recommendations (hygiene, physical distancing), also
nose and mouth protection, testing, use of digital data and
targeted quarantine should be reinforced, see Fig. 6 and
also ref. 89. Assuming, if optimally implemented, that the
rate of new infections caused by an distinct person could
be lower than 1.0, the aforementioned measures might
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Fig. 6 Daily incidence of new infections and future scenarios. The Leopoldina Statement reported the daily incidence of new covid-19 infections
in Germany (a blue dots and line) followed by a statistical modeling of new infections, with full implementation of all proposed measure of
containment (hygiene recommendations, physical distancing, nose and mouth protection, testing, digital data tracking, selected targeted
quarantine) with a very gradual relaxation of restrictive measures imposed to public life (a, green line 1). Conversely, the scenario proposes a fast
reactivation of the infections (a, reddish line 2) if the proposed measures fail to be implemented. The read frequency of cases in South Korea (b),
despite full implementation, shows that sporatic new infections cannot be fully avoided despite serious prevention, resulting in a low grade of
endemic cases88.
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strongly impact in reducing further spread of SARS-CoV-
2, with a simultaneous gradual relaxation of restrictive
measures imposed on public life88.
Conclusion and way forward
After several months’ lockdown, China is now reopen-
ing, facing the risk of second wave of COVD-19. In Italy,
despite lots of patients had already been infected, second
wave of diseases is also challenging should they reopen
the cities, as there is currently no evidence that people
who have recovered are protected from a second infec-
tion. While waiting for an effective vaccine for COVID-19
and for a clear specific treatment, current management is
highly depended on supportive therapy. The best way to
reduce the mortality is therefore related first of all to risk
reduction of SARS-CoV-2 infection. This might be
achieved by combining six main actions: social distance,
masks, hygiene recommendations, contact tracing,
extensive use of early diagnosis tools, and confirmed and
suspected cases quarantine. We learnt from countries like
South Korea and Singapore that such approaches can be
feasible, even in absence of very strict lockdown. Sec-
ondly, strengthen health systems capacity in order to be
fully equipped in terms of medical staff and optimal
equipment’s to prevent medical resource be overwhelmed.
The implementation of these measures is pivotal to pre-
vent re-infections and reactivation of the pandemic;
therefore, the future working society and economy must
adapt to these measures.
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